Drug Profile


Latest Information Update: 03 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gideon Pharmaceuticals
  • Developer Elorac
  • Class Antiallergics; Dibenzoxepins; Oxepins; Skin disorder therapies; Small molecules; Xanthenes
  • Mechanism of Action Adrenergic uptake inhibitors; Histamine H1 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Urticaria
  • Discontinued Allergic rhinitis; Atopic dermatitis; Contact dermatitis

Most Recent Events

  • 03 Mar 2017 Phase-II development for urticaria is ongoing in USA (PO)
  • 03 Mar 2017 Discontinued - Phase-II for Allergic rhinitis in USA (PO)
  • 03 Mar 2017 Elorac plans a phase III trial for Urticaria in USA (PO) (Elorac pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top